Evidence map›Paper›PMID 23942908›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2013

The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis.

Claudia Calcagno, Sarayu Ramachandran, David Izquierdo-Garcia, Venkatesh Mani, Antoine Millon, David Rosenbaum, Ahmed Tawakol, Mark Woodward, Jan Bucerius, Erin Moshier and 6 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00655473 (A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00655473 phase2completednot on this map

A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors

TypeinterventionalSponsorHoffmann-La RocheRan2008 to 2010Enrolled130ConditionsCoronary Heart DiseaseArmsDalcetrapib (RO4607381), Placebo
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pharmacological interventions for asymptomatic carotid stenosis.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  2. Molecular imaging of carotid artery atherosclerosis with PET: a systematic review.European journal of nuclear medicine and molecular imaging · 2020
    Pooled it
  3. Guideline
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Scan-rescan measurement repeatability ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Diagnosis of spinal lesions using perfusion parameters measured by DCE-MRI and metabolism parameters measured by PET/CT.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2020
    Article
  15. Article
  16. Microvasculature and intraplaque hemorrhage in atherosclerotic carotid lesions: a cardiovascular magnetic resonance imaging study.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2019
    Observational
  17. Review
  18. Review
  19. MR/PET Imaging of the Cardiovascular System.JACC. Cardiovascular imaging · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Claudia CalcagnoTranslational and Molecular Imaging Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1234, New York, NY, 10029, USA.
Sarayu Ramachandran
David Izquierdo-Garcia
Venkatesh Mani
Antoine Millon
David Rosenbaum
Ahmed Tawakol
Mark Woodward
Jan Bucerius
Erin Moshier
James Godbold
David Kallend
Michael E Farkouh
Valentin Fuster
James H F Rudd
Zahi A Fayad

Funding

MOUNT SINAI INSTITUTES FOR CLINICAL AND TRANSLATIONAL SCIENCESUL1RR029887 · NCRR · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMPSON, HUGH A · 2009 to 2011
$19.2M
MR/PET Imaging of coronary atherosclerosisR01HL071021 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FAYAD, ZAHI A. · 2002 to 2019
$7.8M
Nanoparticles for Molecular MRI of AtherosclerosisR01HL078667 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FAYAD, ZAHI A. · 2004 to 2008
$2.5M
Novel Imaging to Predict Cardiovascular Events in DiabetesR01HL092989 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FARKOUH, MICHAEL E, FAYAD, ZAHI A. · 2009 to 2010
$1.6M
British Heart Foundation FS/12/29/29463British Heart Foundation PG/09/083/27667NCRR NIH HHS UL1 RR029887NHLBI NIH HHS R01 HL071021NHLBI NIH HHS R01 HL078667NHLBI NIH HHS R01 HL092989PHS HHS NIH/NCRR UL1RR029887PHS HHS NIH/NHLBI R01 HL071021PHS HHS NIH/NHLBI R01 HL078667
6 · The paper itself

Abstract

purposeInflammation and neovascularization in vulnerable atherosclerotic plaques are key features for severe clinical events. Dynamic contrast-enhanced (DCE) MRI and FDG PET are two noninvasive imaging techniques capable of quantifying plaque neovascularization and inflammatory infiltrate, respectively. However, their mutual role in defining plaque vulnerability and their possible overlap has not been thoroughly investigated. We studied the relationship between DCE-MRI and (18)F-FDG PET data from the carotid arteries of 40 subjects with coronary heart disease (CHD) or CHD risk equivalent, as a substudy of the dal-PLAQUE trial (NCT00655473).

methodsThe dal-PLAQUE trial was a multicenter study that evaluated dalcetrapib, a cholesteryl ester transfer protein modulator. Subjects underwent anatomical MRI, DCE-MRI and (18)F-FDG PET. Only baseline imaging and biomarker data (before randomization) from dal-PLAQUE were used as part of this substudy. Our primary goal was to evaluate the relationship between DCE-MRI and (18)F-FDG PET data. As secondary endpoints, we evaluated the relationship between (a) PET data and whole-vessel anatomical MRI data, and (b) DCE-MRI and matching anatomical MRI data. All correlations were estimated using a mixed linear model.

resultsWe found a significant inverse relationship between several perfusion indices by DCE-MRI and (18)F-FDG uptake by PET. Regarding our secondary endpoints, there was a significant relationship between plaque burden measured by anatomical MRI with several perfusion indices by DCE-MRI and (18)F-FDG uptake by PET. No relationship was found between plaque composition by anatomical MRI and DCE-MRI or (18)F-FDG PET metrics.

conclusionIn this study we observed a significant, weak inverse relationship between inflammation measured as (18)F-FDG uptake by PET and plaque perfusion by DCE-MRI. Our findings suggest that there may be a complex relationship between plaque inflammation and microvascularization during the different stages of plaque development. (18)F-FDG PET and DCE-MRI may have complementary roles in future clinical practice in identifying subjects at high risk of cardiovascular events.

Indexed as

Contrast MediaFluorodeoxyglucose F18Magnetic Resonance ImagingMultimodal ImagingPositron-Emission TomographyTomography, X-Ray ComputedCarotid Artery DiseasesFemaleHumansMaleMiddle AgedContrast MediaFluorodeoxyglucose F18

Identifiers

PMID23942908
PMCPMC3823642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.